Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111- labeled B72.3 monoclonal antibody

D. N. Krag, P. Ford, Lloyd H Smith, M. Taylor, Philip D Schneider, J. T. Bushberg, James E Goodnight Jr

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To prospectively evaluate the ability for immunoscintigraphy with monoclonal antibody CYT-103 labeled with indium 111 to detect tumor presence in 15 patients with ovarian cancer undergoing second-look surgery. Design: Prospective, open-label, nonrandomized trial. Setting: Hospital- based nuclear medicine facility and operating room. Study Participants: Patients with previous ovarian cancer scheduled for second-look surgery. Main Outcome Measure: Correctness of prediction of immunoscintigraphy for presence or absence of ovarian cancer compared with serum CA 125 titer and computed tomography. Results: Immunoscintigraphy, computed tomography, and serum CA 125 titer had respective sensitivities of 92%, 42%, and 42%; specificities of 67%, 100%, and 100%; accuracies of 87%, 53%, and 53%; and diagnostic values of 59%, 42%, and 42%. The full regional extent of recurrent tumor was correctly detected in 45% of patients by immunoscintigraphy and in none of the patients by computed tomography. Immunoscintigraphy detected miliary tumor in two of four patients and computed tomography, as expected, was unable to detect miliary disease. Conclusions: Recurrent ovarian cancer often presents as multiple small lesions throughout the abdominal cavity. In this subset of patients, immunoscintigraphy may be particularly well suited for detection of the presence of recurrent tumor.

Original languageEnglish (US)
Pages (from-to)819-823
Number of pages5
JournalArchives of Surgery
Volume128
Issue number7
StatePublished - 1993

Fingerprint

Indium
Ovarian Neoplasms
Monoclonal Antibodies
Second-Look Surgery
Tomography
Neoplasms
Abdominal Cavity
Nuclear Medicine
Operating Rooms
Serum
B72.3 antibody
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Surgery

Cite this

Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111- labeled B72.3 monoclonal antibody. / Krag, D. N.; Ford, P.; Smith, Lloyd H; Taylor, M.; Schneider, Philip D; Bushberg, J. T.; Goodnight Jr, James E.

In: Archives of Surgery, Vol. 128, No. 7, 1993, p. 819-823.

Research output: Contribution to journalArticle

@article{4151ed3a347e4b398966fed39c988eb4,
title = "Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111- labeled B72.3 monoclonal antibody",
abstract = "Objective: To prospectively evaluate the ability for immunoscintigraphy with monoclonal antibody CYT-103 labeled with indium 111 to detect tumor presence in 15 patients with ovarian cancer undergoing second-look surgery. Design: Prospective, open-label, nonrandomized trial. Setting: Hospital- based nuclear medicine facility and operating room. Study Participants: Patients with previous ovarian cancer scheduled for second-look surgery. Main Outcome Measure: Correctness of prediction of immunoscintigraphy for presence or absence of ovarian cancer compared with serum CA 125 titer and computed tomography. Results: Immunoscintigraphy, computed tomography, and serum CA 125 titer had respective sensitivities of 92{\%}, 42{\%}, and 42{\%}; specificities of 67{\%}, 100{\%}, and 100{\%}; accuracies of 87{\%}, 53{\%}, and 53{\%}; and diagnostic values of 59{\%}, 42{\%}, and 42{\%}. The full regional extent of recurrent tumor was correctly detected in 45{\%} of patients by immunoscintigraphy and in none of the patients by computed tomography. Immunoscintigraphy detected miliary tumor in two of four patients and computed tomography, as expected, was unable to detect miliary disease. Conclusions: Recurrent ovarian cancer often presents as multiple small lesions throughout the abdominal cavity. In this subset of patients, immunoscintigraphy may be particularly well suited for detection of the presence of recurrent tumor.",
author = "Krag, {D. N.} and P. Ford and Smith, {Lloyd H} and M. Taylor and Schneider, {Philip D} and Bushberg, {J. T.} and {Goodnight Jr}, {James E}",
year = "1993",
language = "English (US)",
volume = "128",
pages = "819--823",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111- labeled B72.3 monoclonal antibody

AU - Krag, D. N.

AU - Ford, P.

AU - Smith, Lloyd H

AU - Taylor, M.

AU - Schneider, Philip D

AU - Bushberg, J. T.

AU - Goodnight Jr, James E

PY - 1993

Y1 - 1993

N2 - Objective: To prospectively evaluate the ability for immunoscintigraphy with monoclonal antibody CYT-103 labeled with indium 111 to detect tumor presence in 15 patients with ovarian cancer undergoing second-look surgery. Design: Prospective, open-label, nonrandomized trial. Setting: Hospital- based nuclear medicine facility and operating room. Study Participants: Patients with previous ovarian cancer scheduled for second-look surgery. Main Outcome Measure: Correctness of prediction of immunoscintigraphy for presence or absence of ovarian cancer compared with serum CA 125 titer and computed tomography. Results: Immunoscintigraphy, computed tomography, and serum CA 125 titer had respective sensitivities of 92%, 42%, and 42%; specificities of 67%, 100%, and 100%; accuracies of 87%, 53%, and 53%; and diagnostic values of 59%, 42%, and 42%. The full regional extent of recurrent tumor was correctly detected in 45% of patients by immunoscintigraphy and in none of the patients by computed tomography. Immunoscintigraphy detected miliary tumor in two of four patients and computed tomography, as expected, was unable to detect miliary disease. Conclusions: Recurrent ovarian cancer often presents as multiple small lesions throughout the abdominal cavity. In this subset of patients, immunoscintigraphy may be particularly well suited for detection of the presence of recurrent tumor.

AB - Objective: To prospectively evaluate the ability for immunoscintigraphy with monoclonal antibody CYT-103 labeled with indium 111 to detect tumor presence in 15 patients with ovarian cancer undergoing second-look surgery. Design: Prospective, open-label, nonrandomized trial. Setting: Hospital- based nuclear medicine facility and operating room. Study Participants: Patients with previous ovarian cancer scheduled for second-look surgery. Main Outcome Measure: Correctness of prediction of immunoscintigraphy for presence or absence of ovarian cancer compared with serum CA 125 titer and computed tomography. Results: Immunoscintigraphy, computed tomography, and serum CA 125 titer had respective sensitivities of 92%, 42%, and 42%; specificities of 67%, 100%, and 100%; accuracies of 87%, 53%, and 53%; and diagnostic values of 59%, 42%, and 42%. The full regional extent of recurrent tumor was correctly detected in 45% of patients by immunoscintigraphy and in none of the patients by computed tomography. Immunoscintigraphy detected miliary tumor in two of four patients and computed tomography, as expected, was unable to detect miliary disease. Conclusions: Recurrent ovarian cancer often presents as multiple small lesions throughout the abdominal cavity. In this subset of patients, immunoscintigraphy may be particularly well suited for detection of the presence of recurrent tumor.

UR - http://www.scopus.com/inward/record.url?scp=0027319322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027319322&partnerID=8YFLogxK

M3 - Article

C2 - 8317965

AN - SCOPUS:0027319322

VL - 128

SP - 819

EP - 823

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 7

ER -